How does GNPX's PB Ratio compare to its peers?

GNPX is expensive based on its Price-To-Book Ratio (2.4x) compared to the peer average (0.5x).

How does GNPX's PB Ratio compare vs other companies in the US Biotechs Industry?

GNPX is expensive based on its Price-To-Book Ratio (2.4x) compared to the US Biotechs industry average (1.9x).

What is GNPX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate GNPX's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of GNPX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate GNPX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Genprex (Nasdaq:GNPX) - Stock Price, News & Analysis

GNPX Stock Overview

A clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. More details

GNPX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 16.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

+ 3 more risks

Genprex, Inc. Competitors

Pasithea Therapeutics

NasdaqCM:KTTA

US$3.9m

Aptorum Group

NasdaqCM:APM

US$3.8m

Tharimmune

NasdaqCM:THAR

US$3.6m

Silo Pharma

NasdaqCM:SILO

US$3.9m

Price History & Performance

Summary of all time highs, changes and price drops for Genprex
Historical stock prices
Current Share Price	US$1.12
52 Week High	US$14.40
52 Week Low	US$0.28
Beta	-1.29
11 Month Change	-43.43%
3 Month Change	61.08%
1 Year Change	-87.74%
33 Year Change	-98.07%
5 Year Change	-90.37%
Change since IPO	-99.40%

Recent updates

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Shareholder Returns

	GNPX	US Biotechs	US Market
7D	-12.8%	4.0%	2.0%
1Y	-87.7%	18.0%	32.4%

Return vs Industry: GNPX underperformed the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: GNPX underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is GNPX's price volatile compared to industry and market?
GNPX volatility
GNPX Average Weekly Movement	87.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GNPX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GNPX's weekly volatility has increased from 46% to 88% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	21	Ryan Confer	www.genprex.com

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.

Genprex, Inc. Fundamentals Summary

How do Genprex's earnings and revenue compare to its market cap?
GNPX fundamental statistics
Market cap	US$3.60m
Earnings (TTM)	-US$22.71m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is GNPX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNPX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$22.71m
Earnings	-US$22.71m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-6.31
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GNPX perform over the long term?

See historical performance and comparison

GNPX Stock Overview

Risk Analysis

Genprex, Inc. Competitors

NasdaqCM:KTTA

US$3.9m

NasdaqCM:APM

US$3.8m

NasdaqCM:THAR

US$3.6m

NasdaqCM:SILO

US$3.9m

Price History & Performance

Recent News & Updates

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

Recent updates

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Price target increased to US$6.50

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex: Limited Clinical Data To Justify Risk

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$8.25

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%